This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Item Restricted to University of Alberta Users
Log In with CCID to View Item- 112 views
- 26 downloads
Harnessing Metabolic Pathways for the Treatment of Insulin Resistance-Associated Immune Dysfunction
-
- Author(s) / Creator(s)
-
SSHRC NFRF-E awarded 2019: With the requested funding, I will apply my expertise in T cells and metabolism to identify new potential metabolic drugs that can enhance immune function. We hypothesize that a Insulin-Resistance (IR)-related immune and metabolic defect contributes to increased risk of cancer during obesity, and that targeting immune cell metabolism with chemical modulators can improve vaccination-induced protection against cancer. To this end, we propose to carry out drug screening in a novel metabolism-based platform, to identify candidate immune adjuvants capable of boosting anti-tumor immunity when applied in an immunotherapy, with the following aims: I. Delineate the impact of obesity and insulin resistance on T cell-mediated anti-tumor response. II. Identify novel immunotherapeutic agents through metabolic screening. III. Harness cellular metabolic pathways to improve anti-tumor T cell responses.
-
- Date created
- 2018-10-16
-
- Type of Item
- Research Material
-
- License
- ©️Tsai, Sue. All rights reserved other than by permission. This document embargoed to those without UAlberta CCID until 2023.